Price
No data yet.
Social Signal Score
Analyst Ratings
13 analystsRevenue
$8.00MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Jeetinder Singh Mahal
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 22
- Beta
- 3.31
- Country
- US
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- -6.44
Financials
Revenue
$8.00M+0.0%Net Income
$-144.46MEBITDA
$-144.46MFree Cash Flow
$-5.50MEPS (diluted)
$-10.19Shares Outstanding (diluted)
1.08M+18227.2%Operating Expenses
$14.69MCash & Debt
$135.35MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-75.80M | $-118.50 |
| 2024 | $0.00 | $-71.27M | $-146.70 |
| 2023 | $0.00 | $-64.47M | $-185.40 |
| 2022 | $0.00 | $-37.69M | $-309.90 |
| 2021 | $0.00 | $-30.64M | $-806.70 |
| 2020 | $0.00 | $-31.67M | $-5492.40 |
| 2019 | $0.00 | $-4.99M | $0.00 |
Valuation
JSPRhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
80-20.00%Social Signal Score
Mentions (7)
- Newsglobenewswire.com·6d ago·Negative
Jasper Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update REDWOOD CITY, Calif., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a clinical stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases, today reported results for the fiscal quarter ended September 30, 2026, and provided a corporate update.
View source ↗ - Newsglobenewswire.com·13d ago·Negative
…, Inc. Announces Results of the Offer to Purchase Relating to Its Warrants REDWOOD CITY, Calif., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper” or the “Company”), a clinical stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases, today announced the results of its offer to purchase (the “Offer”) all of its outstanding warrants to purchase shares of its common stock, par value $0.0001, which…
View source ↗ - Newsglobenewswire.com·18d ago·Negative
Jasper Therapeutics Announces 1-for-30 Reverse Stock Split REDWOOD CITY, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper” or the “Company”), a clinical stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases, today announced a 1-for-30 reverse stock split (“Reverse Split”) of the Company's common stock (“Common Stock”) that will become effective at 12:01 a.m.
View source ↗ - Newsglobenewswire.com·38d ago·Neutral
…h FSGS , with first patients anticipated to be dosed in first quarter 2027 REDWOOD CITY, Calif., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper” or the “Company”), a clinical stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases, today announced that it has completed enrollment of the IgA nephropathy (IgAN) cohort of its Phase 2 basket study evaluating vensobafusp alfa (KP104), a first-in-c…
View source ↗ - Newsglobenewswire.com·46d ago·Negative
…eutics Announces Commencement of an Offer to Purchase Outstanding Warrants REDWOOD CITY, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper” or the “Company”), a clinical stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases, today reported that it has commenced an offer to purchase (the "Offer") any and all of its outstanding warrants to purchase shares of its common stock, par value $…
View source ↗ - Newsglobenewswire.com·68d ago·Neutral
Jasper Therapeutics Announces Key Regulatory and Clinical Appointments Lisa Pitt, Pharm.D., M.S.J. appointed Senior Vice President, Regulatory Affairs Shiguang Liu, M.D.
View source ↗ - Newsglobenewswire.com·100d ago·Neutral
Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update Acquisition of Kira Pharmaceuticals closed in July creating a combined company with a robust portfolio of clinical stage assets focused on immunologically-driven disorders
View source ↗
Earnings
Mon, Mar 29(in 4 months)
Consensus estimate $-8.11 per share
Typical surprise +96.0% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Nov 16$-10.19 vs $-1.77miss
- Fri, Aug 14$-3.00 vs $-8.03beat
- Fri, May 15$-0.04 vs $-13.80beat
- Mon, Mar 30$-0.32 vs $-23.70beat
- Tue, Nov 11$-1.13 vs $-30.30beat
- Wed, Aug 13$-52.20 vs $-36.00miss
Estimates and results for JSPR via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by JSPR officers and directors.
- Bought
- $7.8m
- Sold
- $106k
17 trades
6 trades
- Ros Matthew Ebought
- Crutcher Patrick Jbought
- Wiggans Thomas Gbought
- Wiggans Thomas Gbought
- Lucas Svetlanabought
- Lucas Svetlanabought
- Martell Ronbought
- Martell Ronbought
77 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in JSPR.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
